Tyra Biosciences, Inc. (TYRA) News
Filter TYRA News Items
TYRA News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Latest TYRA News From Around the Web
Below are the latest news stories about TYRA BIOSCIENCES INC that investors may wish to consider to help them evaluate TYRA as an investment opportunity.
Tyra Biosciences to Participate in 2023 Jefferies London Healthcare ConferenceTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the 2023 Jefferies London Healthcare Conference, taking place November 14-16, 2023. |
Tyra Biosciences Reports Third Quarter 2023 Financial Results and HighlightsTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30, 2023 and highlighted recent corporate progress. |
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual MeetingsTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that TYRA will deliver oral presentations on TYRA-300 for achondroplasia at the American Society for Bone and Mineral Research (ASBMR) and the American Society of Human Genetics (ASHG) 2023 annual meetings. |
We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Tyra Biosciences to Participate at 2023 Cantor Global Healthcare ConferenceTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate at the 2023 Cantor Global Healthcare Conference, taking place September 26-28, 2023, in New York, NY. |
Tyra Biosciences Reports Second Quarter 2023 Financial Results and HighlightsTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended June 30, 2023 and highlighted recent corporate progress. |
Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of AchondroplasiaTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead precision medicine program, TYRA-300, for the treatment of achondroplasia. |
Here's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price StrengthTyra Biosciences, Inc. (TYRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a BetThe consensus price target hints at a 52.2% upside potential for Tyra Biosciences, Inc. (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Tyra Biosciences to Participate in Upcoming Investor ConferencesTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences: |